Microtubule-associated protein 2, an early blood marker of ischemic brain injury

Journal of Neuroscience Research

Volumn 90, Issue 2, 2012, Pages 461-467

  Park, Dongsun ^a   Joo, Seong S ^b   Lee, Hong J ^c,d   Choi, Kyung Chul ^a   Kim, Seung U ^c,d   Kim, Yun Bae ^a,d  

^a Chungbuk National University   (South Korea)

^b Gangneung Wonju National University   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biochemical markers; Cerebrospinal fluid; Glial fibrillary acidic protein (GFAP); Ischemic brain injury; Microtubule associated protein 2 (MAP2); Serum

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PERFUSION; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE MARKER; INJURY SEVERITY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL LESION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TISSUE INJURY; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; BRAIN INJURIES; BRAIN ISCHEMIA; MALE; MICROTUBULE-ASSOCIATED PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 83155182379     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22769     Document Type: Article

References (46)

1. Anand N, Stead LG. 2005. Neuron-specific enolase as a marker for acute ischemic stroke: A systematic review. Cerebrovasc Dis 20: 213-219.
2. Ballough GPH, Martin LJ, Cann FJ, Graham JS, Smith CD, Kling CE, Forster JS, Phann S, Filbert MG. 1995. Microtubule-associated protein 2 (MAP-2): a sensitive marker of seizure-related brain damage. J Neurosci Methods 61: 23-32.
3. Bitsch A, Horn C, Kemmling Y, Seipelt M, Hellenbrand U, Stiefel M, Ciesielczyk B, Cepek L, Banh E, Ratzka P, Prange H, Otto M. 2002. Serum tau protein level as a marker of axonal damage in acute ischemic stroke. Eur Neurol 47: 45-51.
4. Bliss T, Guzman R, Daadi M, Steinberg GK. 2007. Cell transplantation therapy for stroke. Stroke 38: 817-826.
5. Choi EK, Park D, Yon JM, Hur GH, Ha YC, Che JH, Kim J, Shin S, Jang JJ, Hwang SY, Seong YH., Kim DJ, Kim JC, Kim YB. 2004. Protection by sustained release of physostigmine and procyclidine of soman poisoning in rats. Eur J Pharmacol 505: 83-91.
6. Chou J, Harvey BK, Chang CF, Shen H, Morales M, Wang Y. 2006. Neurogenerative effects of BMP7 after stroke in rats. J Neurol Sci 240: 21-29.
7. Cunningham RT, Watt M, Winder J, McKinstry S, Lawson JT, Johnston CF, Hawkins SA, Buchanan KD. 1996. Serum neuron-specific enolase as an indicator of stroke volume. Eur J Clin Invest 26: 298-303.
8. Foerch C, Wunderlich MT, Dvorak F, Humpich M, Kahles T, Goertler M, Alvarez-Sabin J, Wallesch CW, Molina CA, Steinmetz H, Sitzer M, Montaner J. 2007. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 38: 2491-2495.
9. Gilman S. 1998. Imaging the brain. First of two parts. N Engl J Med 338: 812-820.
10. Herrmann M, Vos P, Wunderlich MT, de Bruijn CHMM, Lamers KJB. 2000. Release of glial tissue-specific proteins after acute stroke. A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 31: 2670-2677.
11. Ilg EC, Schäfer BW, Heizmann CW. 1996. Expression pattern of S100 calcium-binding proteins in human tumors. Int J Cancer 68: 325-332.
12. Johnson GVW, Jope RS. 1992. The role of microtubule-associated protein 2 (MAP-2) in neuronal growth, plasticity, and degeneration. JNeurosci Res 33: 505-512.
13. Kane I, Whiteley WN, Sandercock PAG, Wardlaw JM. 2008. Availability of CT and MR for assessing patients with acute stroke. Cerebrovasc Dis 25: 375-377.
14. Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Stevens GH, Masaryk T, Ayumar B, Vogelbaum MA, Barnett GH, Janigro D. 2003. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer 97: 2806-2813.
15. Kaur C, Ling EA. 2008. Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res 5: 71-81.
16. Kim JS, Yoon SS, Kim YH, Ryu JS. 1996. Serial measurement of interleukin-6, transforming growth factor-β, and S-100 protein in patients with acute stroke. Stroke 27: 1553-1557.
17. Kitagawa K, Matsumoto M, Ninobe M, Mikoshiba K, Hata R, Ueda H, Handa N, Fukunaga R, Isaka Y, Kimura K, Kamada T. 1989. Microtubule-associated protein 2 as a sensitive marker for cerebral ischemic damage-immunohistochemical investigation of dendritic damage. Neuroscience 31: 401-411.
18. Kitano H, Nishimura H, Tachibana H, Yoshikawa H, Matsuyama T. 2004. ORP150 ameliorates ischemia/reperfusion injury from middle cerebral artery occlusion in mouse brain. Brain Res 1015: 122-128.
19. Lamers KJB, Vos P, Verbeek MM, Rosmalen F, van Geel WJ, van Engelen BG. 2003. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res Bull 61: 261-264.
20. Longa EZ, Weinstein PR, Carlson S, Cummins R. 1989. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84-91.
21. Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR, Kanner A, Ayumar B, Albensi B, Cavaglia M, Janigro D. 2003. Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci 21: 109-121.
22. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. 2004. Peripheral markers of blood-brain barrier damage. Clin Chim Acta 342: 1-12.
23. O'Donell SL, Frederick TJ, Krady JK, Vannucci SJ, Wood TL. 2002. IGF-I and microglia/macrophage proliferation in the ischemic mouse brain. Glia 39: 85-97.
24. Park D, Jeon JH, Shin S, Jang JY, Choi B, Nahm SS, Kang JK, Hwang SY, Kim JC, Kim YB. 2008. Debilitating stresses do not increase blood-brain barrier permeability: lack of the involvement of corticosteroids. Environ Toxicol Pharmacol 26: 30-37.
25. Pastori C, Regondi MC, Librizzi L, de Curtis M. 2007. Early excitability changes in a novel acute model of transient focal ischemia and reperfusion in the in vitro isolated guinea pig brain. Exp Neurol 204: 95-105.
26. Puka-Sundvall M, Hagberg H, Andine P. 1994. Changes in extracellular calcium concentrations in the immature rat cerebral cortex during anoxia is not influenced by MK-801. Brain Res Dev Brain Res 77: 146-150.
27. Reiber H. 2003. Proteins in cerebrospinal fluid and blood: barriers. CSF flow rate and source-related dynamics. Restor Neurol Nuerosci 21: 79-96.
28. Rosengren LE, Wikkelsø C, Hagberg L. 1994. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Mehods 51: 197-204.
29. Saatman KE, Feeko KJ, Pape RL, Raghupathi R. 2006. Differential behavioral and histopathological responses to graded cortical impact injury in mice. J Neurotrauma 23: 1241-1253.
30. Shepherd GM. 1994. Neuron and glia. In: Shepherd GM, editor. Neurobiology. New York: Oxford University Press. p 36-64.
31. Stein DT, Vannucci RC. 1988. Calcium accumulation during evolution of hypoxic-ischemic brain damage in the immature rat. J Cereb Blood Flow Metab 8: 834-842.
32. Steiner J, Bernstein HG, Bogerts B, Gos T, Richter-Landsberg C, Wunderlich MT, Keilhoff G. 2008. S100B is expressed in, and released from, OLN-93 oligodendrocytes: influence of serum and glucose deprivation. Neuroscience 154: 496-503.
33. Tanaka Y, Marumo T, Omura T, Yoshida S. 2008. Relationship between cerebrospinal and peripheral S100B levels after focal cerebral ischemia in rats. Neurosci Lett 436: 40-43.
34. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 1995. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581-1587.
35. Tucker RP. 1990. The roles of microtubule-associated proteins in brain morphogenesis:a review. Brain Res Brain Res Rev 15: 101-120.
36. Vannucci RC, Connor JR, Mauger DT, Palmer C, Smith MB, Towfighi J, Vannucci SJ. 1999. Rat model of perinatal hypoxic-ischemic brain damage. J Neurosci Res 55: 158-163.
37. Vissers JLM, Mersch MEC, Rosmalen CF, van Heumen MJMT, van Geel WJA, Lamers KJB, Rosmalen FMA, Swinkels LMJW, Thomsen J, Herrmann M. 2006. Rapid immunoassay for the determination of glial fibrillary acidic protein (GFAP) in serum. Clin Chim Acta 366: 336-340.
38. Vos PE, van Gils M, Beems T, Zimmerman C, Verbeek MM. 2006. Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity. Eur J Neurol 13: 632-638.
39. Wunderlich MT, Ebert AD, Kartz T, Goertler M, Jost S, Herrmann M. 1999. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 30: 1190-1195.
40. Wunderlich MT, Wallesch CW, Goertler M. 2004. Release of neurochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci 227: 49-53.
41. Wunderlich MT, Wallesch CW, Goertler M. 2006. Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke. Eur J Neurol 13: 1118-1123.
42. Yoshimi K, Takeda M, Nishimura T, Kudo T, Nakamura Y, Tada K, Iwata N. 1991. An immunohistochemical study of MAP2 and clathrin in gerbil hippocampus after cerebral ischemia. Brain Res 560: 149-158.
43. Yushmanov VE, Kharlamov A, Simplaceanu E, Williams DS, Jones SC. 2006. Differences between arterial occlusive and cortical photothrombosis stroke models with magnetic resonance imaging and microtubule-associated protein-2 immunoreactivity. Magn Reson Imag 24: 1087-1093.
44. Zhang ZG, Bower L, Zhang RL, Chen S, Windham JP, Chopp M. 1999. Three-dimensional measurement of cerebral microvascular plasma perfusion, glial fibrillary acidic protein and microtubule associated protein-2 immunoreactivity after embolic stroke in rats: a double fluorescent labeled laser-scanning confocal microscopic study. Brain Res 844: 55-66.
45. Zimmer DB, Cornwall EH, Landar A, Song W. 1995. The S100 protein family: history, function, and expression. Brain Res Bull 37: 417-429.
46. Zivin JA. 1999. Thrombolytic stroke therapy: past, present, and future. Neurology 53: 14-19.